Peptide Purity and HPLC Testing: How It Works and Why It Matters
What does "peptide purity" actually mean?
Purity sounds straightforward, but for synthetic peptides, it's a nuanced concept with multiple dimensions. When a supplier states "98% or greater purity," they're typically referring to HPLC purity — the proportion of the total UV-absorbing material that corresponds to the target peptide, as measured by high-performance liquid chromatography.
But HPLC purity tells you only part of the story. It doesn't account for water content, residual salts, or counterions. A peptide with 98% HPLC purity and 70% peptide content contains less actual peptide per milligram of powder than those numbers might suggest at first glance. A researcher who ignores peptide content and works purely from total powder weight will overdose in terms of salt and underdose in terms of active peptide — a systematic error that can skew entire datasets.
Understanding what purity means — and what the analytical methods behind it can and can't detect — is fundamental to good experimental design. Impurities affect dose calculations, assay sensitivity, and reproducibility. Ignoring them doesn't make them go away; it just makes your data harder to interpret and harder to publish convincingly.
How does HPLC work for peptide analysis?
HPLC is the workhorse technique for peptide quality control, used across virtually every synthetic peptide laboratory worldwide. It's been the standard since the 1980s, and while newer techniques exist, nothing has displaced RP-HPLC for routine peptide purity assessment. The principle is separation based on differential interaction with a stationary phase.
Reverse-phase HPLC (RP-HPLC)
This is the standard method for peptide purity analysis. Here's the process in practical terms:
1. Sample dissolution: The peptide is dissolved in an appropriate solvent — typically water with 0.1% trifluoroacetic acid (TFA). TFA acts as an ion-pairing agent, protonating basic groups on the peptide and improving chromatographic peak shape.
2. Injection: A precise volume (usually 10–50 microL containing 10–100 microg of peptide) is injected onto the chromatographic column via an autosampler.
3. Separation: The column contains silica particles bonded with C18 (octadecyl) hydrocarbon chains. Peptides interact with these chains based on their hydrophobicity — the more hydrophobic residues a peptide has, the more strongly it binds. A gradient of increasing organic solvent (acetonitrile, usually) progressively elutes peptides in order of increasing hydrophobicity.
4. Detection: As peptides elute from the column, they pass through a UV detector set at 214 nm or 220 nm (the peptide bond absorption wavelength). Every peptide bond absorbs at this wavelength, making it a universal detection method for peptides. The detector records a chromatogram — a plot of absorbance versus time.
5. Integration: Software calculates the area under each peak. The target peptide peak's area as a percentage of total peak area gives the HPLC purity. Modern chromatography data systems (Empower, Chromeleon, OpenLAB) perform this automatically, but the integration parameters can significantly affect the result — baseline definition, peak start/end assignment, and threshold settings all influence the final number.
Column specifications matter
Typical analytical conditions for peptide QC:
- Column: C18, 4.6 x 150 mm or 250 mm, 5 micrometre particle size, 300 angstrom pore size
- Mobile phase A: Water with 0.1% TFA
- Mobile phase B: Acetonitrile with 0.1% TFA
- Gradient: 5–65% B over 30 minutes (varies by peptide hydrophobicity)
- Flow rate: 1.0 mL/min
- Detection: 214 nm UV
- Temperature: 25–40 degrees C (higher temperatures improve peak shape for some peptides)
- Injection volume: 10–20 microL
The 300 angstrom pore size is critical — standard 100 angstrom pores used for small molecules don't allow peptides larger than about 15 amino acids to interact properly with the stationary phase inside the pores. This leads to poor peak shape, reduced resolution, and inaccurate purity assessment. Using the wrong column pore size is a surprisingly common error in labs new to peptide analysis.
What impurities does HPLC detect?
RP-HPLC is excellent at detecting several categories of synthesis-related impurities:
Deletion peptides
During solid-phase peptide synthesis (SPPS), each amino acid coupling step has a yield below 100% — typically 99.0–99.8% per step. If a coupling fails, you get a peptide missing one or more amino acids — a deletion peptide. For a 15-amino acid peptide like BPC-157 with 14 coupling steps, even at 99.5% efficiency per step, roughly 7% of the crude product will contain at least one deletion. These deletion peptides are typically the most abundant impurities and elute at different retention times from the target peptide because the missing residue(s) alter overall hydrophobicity.
Truncated sequences
Premature chain termination produces peptides that are correct up to a certain point but shorter than intended. These "truncates" result from incomplete deprotection or irreversible side reactions during synthesis. They're usually well separated by RP-HPLC because they differ significantly in size and hydrophobicity from the full-length target.
Oxidised species
Oxidation of methionine to methionine sulfoxide (+16 Da) or cysteine to cysteic acid changes the peptide's polarity and retention time. Oxidised species typically appear as distinct peaks — usually eluting earlier than the parent peptide because the oxidised residues are more polar. For methionine-containing peptides like Semax and TB-500, oxidation is one of the first degradation products to appear during storage.
Deamidated products
Asparagine-to-aspartate conversion (+1 Da) adds a negative charge and slightly alters hydrophobicity. Detection depends on the specific sequence context and may require optimised chromatographic conditions. Asn-Gly sequences deamidate fastest; Asn-Pro sequences are most resistant.
Racemised residues
D-amino acid incorporation (racemisation) during synthesis produces diastereomers — peptides with the same sequence but different stereochemistry at one or more positions. Some diastereomers are resolved by RP-HPLC, particularly if the racemised residue significantly alters the peptide's secondary structure or hydrophobic surface. Others co-elute with the target peptide — a known limitation of HPLC that makes mass spectrometry confirmation essential.
Insertion peptides
Double coupling — where the same amino acid is incorporated twice — produces insertion peptides. These are rarer than deletions but occur more frequently when highly activated amino acids are used. They elute at different retention times due to the additional residue's effect on overall hydrophobicity.
What can't HPLC detect?
RP-HPLC has genuine blind spots that researchers need to understand:
- Co-eluting impurities: If an impurity has the same retention time as the target peptide, it won't be resolved as a separate peak. This is why mass spectrometry confirmation is essential — MS can detect co-eluting species that HPLC alone would miss entirely.
- Non-UV-absorbing impurities: Residual TFA, acetate counterions, water, inorganic salts, and some small-molecule contaminants don't absorb at 214 nm and won't appear on the chromatogram. They could constitute 15–40% of the powder weight without registering.
- Peptide content: HPLC tells you the purity of the peptide fraction but not what percentage of the total powder weight is peptide. For that, you need a separate peptide content determination by amino acid analysis, nitrogen analysis (Kjeldahl or combustion), or UV quantitation against a calibrated standard.
- Endotoxin: Bacterial lipopolysaccharide contamination is invisible to HPLC. The LAL assay is required for detection.
- Residual solvents: Organic solvents from synthesis and purification (DMF, NMP, DCM, diethyl ether) are not detected at 214 nm. GC headspace analysis is needed for residual solvent quantification.
This is why a comprehensive Certificate of Analysis includes both HPLC and mass spectrometry data at minimum. Neither technique alone tells the complete story. Visit Read more to see how Premio Peptides combines multiple analytical methods for a thorough quality picture.
How do you interpret an HPLC chromatogram?
Reading a chromatogram is a learned skill. Here's what to look for:
The main peak
Should be sharp, symmetrical, and dominant — ideally accounting for the stated purity percentage of total peak area. Its retention time should match the expected value for that peptide under the stated conditions. A broad or asymmetric main peak can indicate:
- Column degradation or overloading
- Peptide conformational heterogeneity (some peptides exist in multiple conformations that interconvert slowly on the chromatographic timescale)
- Multiple closely-related impurities that aren't fully resolved
Minor peaks
Small peaks before or after the main peak represent impurities. Their size relative to the main peak determines the purity percentage. A chromatogram with one dominant peak and minimal "noise" is what you want to see. Pay attention to the number and pattern of minor peaks — a few well-defined small peaks suggest specific, identifiable impurities, while a broad "hump" of many tiny peaks suggests a complex mixture that may indicate poor synthesis quality.
Baseline
Should be stable and relatively flat. A rising baseline suggests column bleed, solvent impurities, or gradient artefacts. Integration against a noisy baseline reduces purity measurement accuracy. A good baseline drift is less than 0.005 AU over the analysis time.
Retention time
Shifts in retention time between runs of the same peptide suggest either column ageing, temperature fluctuations, or mobile phase composition changes. Consistent retention time is a sign of good analytical practice. A CoA should report the retention time of the main peak.
What purity level do you need?
This depends entirely on your application:
- Cell-based assays: 95% minimum. Impurities can be cytotoxic or biologically active, confounding results. 98% or greater is preferred and is the standard for published work.
- In vivo studies: 98% or greater. Impurities in animal models can cause off-target effects, immune reactions, or injection site inflammation that muddy your data.
- Structural studies (NMR, X-ray): 95% or greater, but with confirmed mass spec identity. Co-eluting impurities that HPLC misses can ruin crystallisation or produce ambiguous NMR spectra.
- Screening/preliminary assays: 90% may be acceptable for early-stage work where you're looking for binary activity/no-activity results. But be cautious — if your screening hit turns out to be driven by an impurity, you'll have wasted considerable follow-up effort.
- Binding affinity measurements: 98% or greater. Impurities that compete for the same binding site produce artefactual Ki or Kd values.
Premio Peptides supplies research-grade peptides at 98% or greater HPLC purity as standard. For applications requiring higher purity or additional analytical characterisation, see our specifications at Read more.
Beyond HPLC: complementary analytical methods
A robust QC programme doesn't rely on HPLC alone:
- Mass spectrometry (MS): Confirms molecular identity by measuring molecular weight. Essential for detecting co-eluting impurities and sequence errors. ESI-MS or MALDI-TOF are standard.
- Amino acid analysis (AAA): Confirms amino acid composition, determines peptide content, and can detect sequence errors. The gold standard for peptide content quantification.
- Endotoxin testing (LAL): Critical for peptides intended for cell culture or in vivo use. Endotoxin contamination is invisible to other methods and confounds biological assays.
- Karl Fischer titration: Measures water content with high precision. Combined with AAA, gives a complete picture of what the powder actually contains.
- Residual solvent analysis (GC): Confirms that synthesis solvents have been adequately removed. Important for peptides intended for cell culture.
For storage guidance to maintain the purity you've verified, see Read more. And for a closer look at individual peptide specifications, explore compound pages like Read more.
References
1. Verbeke, F. et al. (2015). "Quality evaluation of synthetic peptides using LC-MS." *Journal of Chromatography A*, 1422, 30–38. DOI: 10.1016/j.chroma.2015.10.023
2. D'Hondt, M. et al. (2014). "Quality analysis of synthetic peptides for research and clinical use." *Journal of Pharmaceutical and Biomedical Analysis*, 101, 2–16. DOI: 10.1016/j.jpba.2014.06.023
3. Mant, C.T. et al. (2007). "HPLC analysis and purification of peptides." *Methods in Molecular Biology*, 386, 3–55. DOI: 10.1007/978-1-59745-430-8_1
---
Research Use Only Disclaimer
All peptides sold by Premio Peptides are strictly for laboratory and research purposes. They are not intended for human consumption, therapeutic use, or as food supplements. Researchers are responsible for ensuring compliance with all applicable regulations in their jurisdiction. Premio Peptides does not condone or encourage the use of these products outside a controlled research environment.
*Published by the Premio Peptides research team. Peer-reviewed sources cited throughout.*